Phase 4 N=28 Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Influenza
Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=133 Influenza Immunity in Children
Influenza
Primary: Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects — .010; 0.003; 0.009; 0.002 percentage of T cells — p=0.005
Phase 2 N=30 Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
Cystic Fibrosis · Bronchiectasis Adult · Non-Tuberculous Mycobacteria
Primary: BCG Uptake — 48.06; 0.84; 35.97 spot forming units
Phase 4 N=125 Development of Childhood Anti-Influenza Immunity
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
N/A N=544 Feasibility of Cocooning Immunization Strategy With Influenza Vaccine
Influenza
Primary: Influenza Vaccine Coverage (Percent) for New Mothers of Newborns — 70; 64 Percentage of Participants
N/A N=43 Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
Immunosuppression
Primary: Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination — 19; 5; 6 participants
Phase 2 N=127 Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older
Breast Cancer · Lung Cancer · Prostate Cancer
Primary: Determine Response Rate of Patients > or = to 65 Yrs Diagnosed — 63; 24 participants
Phase 4 N=59 Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis
Rabies
Primary: Protective Humoral Immune Response at 1 Month Post First Vaccination. — 12; 12; 12; 11 Participants
Phase 4 N=91 B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 14; 38; 36 Participants
Phase 3 N=7,250 Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Influenza
Primary: Efficacy of an Investigational Vero Cell-derived Influenza Vaccine to Prevent Infection With an Influenza Virus That is Antigenically Similar to One of the Three Strains…
Phase 4 N=162 The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine
Pneumococcal Pneumonia · Influenza
Primary: The Number of Patients With Positive Antibody Response in Serotype 23F of Pneumococcal Antibody. — 63; 59 Participants
Phase 4 N=280 Immunomodulation Following Transfusion
Blood Component Transfusion
Primary: Number of Participants With Changes in the Production of Antibody to HLA Antigens — 2; 6; 2; 5 Participants
N/A N=133 Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement
Infections After Lung Transplant
Primary: The Primary Outcome Will be the Total Number of Days With Pneumonia. — 1714; 51 Number of days
Phase 2 N=56 Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants
Complication Due to Immunization
Primary: The Change in the Number of CRE (Extracted From Printed Monitoring Tracings Compared to Noted Nurses' Surveillance) Following the First Dose of Pentavalent Vaccine in…
Phase 2 N=43 The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination
Yellow Fever
Primary: Peak Neutralizing Antibody Titer — 1.37 Log YF antibody titer
N/A N=148 Healthy, Immunized Communities Study
Vaccine Hesitancy · Communicable Diseases in Children
Primary: Percentage of Participants With Intent to Vaccinate Adolescent Child (Tdap, MCV, HPV) — 74.3; 83.3; 97.9; 93.0 percentage of participants
Phase 4 N=165 Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
Plasma Cell Neoplasm
Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants
Phase 4 N=20 Immune Response Following Seasonal Influenza Vaccination
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
N/A N=75 Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge
Respiratory Syncytial Virus Infections · Influenza, Human
Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale
N/A N=50 Effect of Obesity on Immune Response to Pneumovax 23
Obesity
Primary: Anti-pneumococcal Antibodies Between the Groups — 34.1; 19.8 titer
Phase 4 N=8 B-cell Immunity to Influenza (SLVP017)- Year 5, 2013
Influenza
Primary: Number of Participants Who Received Influenza Vaccine — 1; 7 Participants
Phase 4 N=352 Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients
Hepatitis B Vaccine
Primary: Anti-HBs Seroconversion Rate at Month 7 — 118; 132 Participants
Phase 4 N=20 Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine
Influenza
Primary: Number of Participants Who Shed Virus — 0 participants
Phase 2 N=52 Combination Vaccination Before HIV Treatment Interruption
HIV Infections
Primary: Time to Detectable Virus in the Remune Plus ALVAC Group and the Placebo Group — 24.5; 13.5 days
N/A N=15 γ-irradiated BCG to Train Innate Immunity
Innate Immune Response
Primary: Cytokine Production Measured by ELISA Compared to Baseline — 1.2 ratio
Phase 4 N=70 Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics
Asthma
Primary: Immunogenicity of Pneumococcal Vaccination — 0.05; 0.05 [µg/ml]
Phase 4 N=219 Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
Chronic Obstructive Pulmonary Disease · Asthma · Pneumococcal Infections
Primary: Number of Patients Without Exacerbations of the Underlying Disease, Antibiotic Use and Hospitalisation. — 3; 5; 1; 0 Participants — p=<0.05
Phase 2 N=46 Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans
Healthy Volunteers
Primary: Virus Infection — 8; 18 Participants
Phase 2 N=34 Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
Tick Borne Encephalitis
Primary: Outcome of the Neutralization Test (Number of Subjects With Antibody Response Measured by Neutralization Assay) — 6; 14 Participants — p=<0.001